Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VRCA vs DMAC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DMAC Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–1 Matrix Metrics)

DMAC Overall Winner 6-Pillar Tally: VRCA 2 – 3 DMAC (1 Tie) Matrix Metrics: VRCA 1 – 7 DMAC

As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) is the stronger overall head-to-head candidate over Verrica Pharmaceuticals Inc. (VRCA) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). VRCA carries a Unified Composite Score of 38.5/100 (SELL) at $3.37 (N/M Forward P/E, -87.2% operating margin), whereas DMAC carries 46.3/100 (HOLD) at $8.41 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: VRCA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.5); meanwhile DMAC trades in a Neutral technical trend (SURGE options phase, RSI 44.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VRCA vs DMAC
VRCA NASDAQ
Verrica Pharmaceuticals Inc. Common Stock
Pharmaceutical Preparations
$3.37
-5.48% 1D
Market Cap $63.9M
TTM Revenue $30M
Forward P/E N/M
Beta / 30D Vol 1.93β · 92% Vol
Unified Composite Score
38.5 / 100 SELL
Tech 41.0 Fund 37.0 Flow 50.0 Mom 44.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.8%), weak momentum, RSI 44
RSI-14: 43.5 · SMA20: $3.48 · SMA50: $4.02
DMAC NASDAQ Head-to-Head Winner
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.41
-4.27% 1D
Market Cap $503.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.74β · 98% Vol
Unified Composite Score
46.3 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 65.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 44.7 · SMA20: $9.24 · SMA50: $8.24

6-Pillar Scorecard Institutional Category Breakdown (VRCA 2 – 3 DMAC)

Columns: Metric · VRCA · DMAC
1. Valuation Multiples VRCA
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 1.5x N/M
2. Growth & Scale DMAC
Revenue Growth (YoY) -53.9% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $30M N/A
Market Cap $63.9M $503.1M
3. Profitability & Quality DMAC
Gross Margin 37.7% N/A
Operating Margin -87.2% 0.0%
Net Profit Margin -102.8% 0.0%
Return on Equity (ROE) -240.4% -114.6%
4. Balance Sheet & Cash Flow VRCA
Cash Generation (TTM) -$14M -$32M
Cash Flow Margin -46.5% N/A
Net Cash / Leverage $19M Net Cash $4.9M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DMAC
Options Structure Phase UNCLASSIFIED SURGE
Current IV / %ile N/A (N/A) 106.3% (14th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VRCA (1) vs DMAC (7)
Institutional Metric VRCA DMAC Criterion Row Edge
Market Capitalization
Scale
$63.9M $503.1M Larger Scale DMAC
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-53.9% +0.0% Higher Growth DMAC
Operating Margin (TTM)
Profitability
-87.2% 0.0% Higher Margin DMAC
Net Profit Margin
Profitability
-102.8% 0.0% Higher Margin DMAC
Return on Equity (ROE)
Capital Efficiency
-240.4% -114.6% Higher ROE DMAC
52-Week Range Position
Momentum
4% ($3–$10) 55% ($5–$11) Stronger Trend DMAC
Beta / 30D Volatility
Risk Regime
1.93β · 92% Vol 1.74β · 98% Vol Lower Realized Risk VRCA
Unified Institutional Score
Composite Signal
38.5 / 100 (SELL) 46.3 / 100 (HOLD) Higher Composite DMAC
Trailing 12M Revenue (USD)
Operating Scale
$30M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
37.7% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.5x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$14M ($19M Net Cash) -$32M ($4.9M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DMAC +17.56 pp
VRCA: -6.4% · DMAC: +11.16%
3M Horizon DMAC +55.41 pp
VRCA: -28.1% · DMAC: +27.31%
6M Horizon DMAC +90.82 pp
VRCA: -42.67% · DMAC: +48.15%
1Y Horizon DMAC +68.31 pp
VRCA: -13.05% · DMAC: +55.26%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period VRCA Revenue DMAC Revenue VRCA Op. Margin DMAC Op. Margin Margin Leader
FY2018 N/A $0M N/A -1352.2% DMAC
FY2021 $10M N/A -257.6% N/A VRCA
FY2022 $10M N/A -235.8% N/A VRCA
FY2023 $10M N/A -1283.4% N/A VRCA
FY2024 $10M N/A -871.3% N/A VRCA
FY2025 $40M N/A -34.2% N/A VRCA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VRCA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VRCA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DMAC SURGE
8d in phase · OBV NEUTRAL
Current IV 106.3%
IV Percentile 14th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact DMAC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VRCA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $63.9M market capitalization and -87.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DMAC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $503.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VRCA vs DMAC Key Questions & Quantitative Answers

As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) is the stronger overall head-to-head candidate over Verrica Pharmaceuticals Inc. (VRCA) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). VRCA carries a Unified Composite Score of 38.5/100 (SELL) at $3.37 (N/M Forward P/E, -87.2% operating margin), whereas DMAC carries 46.3/100 (HOLD) at $8.41 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: VRCA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.5); meanwhile DMAC trades in a Neutral technical trend (SURGE options phase, RSI 44.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DMAC leads the Growth & Scale pillar: VRCA posts -53.9% YoY revenue growth and +0.0% YoY earnings growth on $30M TTM revenue (37.7% gross margin, -87.2% operating margin), compared with DMAC at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 6-period historical trajectory (FY2018 to FY2025), VRCA cumulative revenue shifted +300.0% while DMAC shifted N/A. In operating R&D and SG&A reinvestment, VRCA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DMAC.

VRCA screens cheaper on headline valuation multiples. VRCA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.5x EV/Revenue (-46.5% FCF margin), whereas DMAC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VRCA (-240.4% ROE) versus DMAC (-114.6% ROE) capital efficiency.

In options market volatility and institutional positioning, VRCA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.93β · 92% Vol realized risk). By comparison, DMAC carries 106.3% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.74β · 98% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.